HDAC9 and lung carcinoma: Our goals were to profile the sensitivity of cancer cells to the HDAC inhibitors trichostatin A and depsipeptide, to compare their relative potency and specificity across panels of lung cancer, breast cancer and melanoma cell lines, and to define phenotypes unique to each inhibitor.